礼来明星产品替尔泊肽正式在华上市

时代财经
02 Jan

1月2日,礼来中国宣布替尔泊肽注射液(商品名:穆峰达)正式在华上市,同时覆盖降糖和减重两项适应症,以上适应症分别于2024年5月和7月获得国家药品监督管理局批准。礼来中国总裁兼总经理德赫兰强调: “历经百年,礼来始终与中国并肩,共同面对重大疾病挑战。在代谢性疾病日益成为公共健康负担的今天,我们承诺将携手政府和行业伙伴,通过我们创新的双靶点降糖、减重疗法,支持国家 ‘体重管理年’计划和慢性病综合防治...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10